Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07222267 · ClinicalTrials.gov registry record · Phase 1
An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors
A Phase 1 study of Breast Cancer and Advanced Solid Tumor, sponsored by BeOne Medicines.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 86
- Enrollment target
- 12
- Study locations
NCT07222267 is a Phase 1 study of Breast Cancer and Advanced Solid Tumor that is actively recruiting participants, run by BeOne Medicines. The registered enrollment target is 86 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower). The trial reports 12 study locations across 10 states.
The verdict
NCT07222267, a Phase 1 study of Breast Cancer and Advanced Solid Tumor, is actively recruiting participants, sponsored by BeOne Medicines.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 86 participants
- Enrollment target
- 12
- Study locations
Study Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-75202 (KAT6A/B inhibitor) alone and in combination with other therapies in participants with breast cancer and other advanced solid tumors.
Conditions Studied
Interventions
- DRUG Aromatase Inhibitor
- DRUG BG-75202
- DRUG CDK4 Inhibitor
- DRUG Estrogen Receptor Antagonist
Study Locations (12)
Texas
- Next Oncology Austin - Austin
- The University of Texas Md Anderson Cancer Center - Houston
Beijing Municipality
- Cancer Hospital Chinese Academy of Medical Sciences - Beijing
- Beijing Cancer Hospital - Beijing
Missouri
- Washington University in St Louis - St Louis
New South Wales
- Blacktown Cancer and Haematology Centre - Blacktown
South Australia
- Cancer Research South Australia - Adelaide
Victoria
- Peter Maccallum Cancer Centre - Melbourne
Guangdong
- Sun Yat Sen University Cancer Centerhuangpu Branch - Guangzhou
Jiangsu
- Jiangsu Province Hospital Longjiang Branch - Nanjing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2025-12-11 |
| Est. Completion | 2037-01-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07222267
The ClinicalTrials.gov registry entry for NCT07222267 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 86 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower). The listed sponsor is BeOne Medicines, which has 29 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Breast Cancer appearing as the primary indexed condition, and to 4 interventions - of which Aromatase Inhibitor is the first listed.
NCT07222267 reports 12 study locations spanning 10 distinct geographic areas - top geographies include Texas, Beijing Municipality, Missouri.
Frequently Asked Questions
What is clinical trial NCT07222267 about?
NCT07222267 is a clinical study titled "An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors". The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-75202 (KAT6A/B inhibitor) alone and in combination with other therapies in participants with breast cancer and other advanced solid tumors.
What is the current status of trial NCT07222267?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 86 participants. The study started on 2025-12-11. Estimated completion is 2037-01-13.
What conditions does trial NCT07222267 study?
This clinical trial studies the following conditions: Breast Cancer, Advanced Solid Tumor.
What interventions are being tested in trial NCT07222267?
The interventions under investigation include: Aromatase Inhibitor (DRUG), BG-75202 (DRUG), CDK4 Inhibitor (DRUG), Estrogen Receptor Antagonist (DRUG).
Who is sponsoring clinical trial NCT07222267?
This trial is sponsored by BeOne Medicines, which has 29 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07222267 being conducted?
This trial has 12 study locations across Missouri, Texas, New South Wales, South Australia, Victoria. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
VS-6766+Abema+Fulv in Met HR+/HER- BC
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.